Metraipolis › archive › dc_afff2eecc4f0

Nivolumab plus ipilimumab versus lenvatinib or sorafenib for US and Chinese patients with unresectable hepatocellular carcinoma: a cost-effectiveness analysis — Europe PMC PMID:41602061

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41602061
DOI: 10.3389/fpubh.2025.1726477
License (as archived): solo-consultazione
Archived: 2026-11-06T21:05:32.803Z
SHA-256 of the archived text: 639b4989f6e49f5518b5d99231358a8d6dfc182888353621497a5921ce88ac71
Stable URL of this page: https://metraipolis.com/documento/dc_afff2eecc4f0

How to cite

Nivolumab plus ipilimumab versus lenvatinib or sorafenib for US and Chinese patients with unresectable hepatocellular carcinoma: a cost-effectiveness analysis — Europe PMC PMID:41602061 — Europe PMC (en), https://europepmc.org/article/MED/41602061 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_afff2eecc4f0 (Metraipolis archive dc_afff2eecc4f0, sha256 639b4989f6e49f5518b5d99231358a8d6dfc182888353621497a5921ce88ac71)

BibTeX

@misc{dcafff2eecc4f0,
  title = {Nivolumab plus ipilimumab versus lenvatinib or sorafenib for US and Chinese patients with unresectable hepatocellular carcinoma: a cost-effectiveness analysis — Europe PMC PMID:41602061},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41602061},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_afff2eecc4f0; sha256 639b4989f6e49f5518b5d99231358a8d6dfc182888353621497a5921ce88ac71},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41602061. Agents can read the archived copy with the MCP tool read_document.